PROCEPT BioRobotics Corporation (PRCT) Releases Q4 2025 Earnings: Revenue Growth but Continued Losses

PROCEPT BioRobotics Corporation (PRCT) reported Q4 2025 results showing revenue growth but continued losses. Key fourth-quarter results:

Revenue of $76.4 million, up 11.9% year‑over‑year and below the consensus estimate of $96.0 million.

Gross profit of $46.3 million, up 6.1% year‑over‑year; cost of sales was $30.1 million, up 22.4%.

Operating loss of $31.0 million, an improvement of 57.5% year‑over‑year.

Net loss attributable to common shareholders of $29.8 million, improved 58.3% year‑over‑year.

Additional items from the quarter:

Diluted loss per share of -$0.53, improved about 55.9% year‑over‑year versus an estimate of -$0.33.

Cash used in operating activities of $10.3 million, a deterioration of 68.1% year‑over‑year.

Purchases of property, plant and equipment of $1.9 million, up 57.6% year‑over‑year.

Cash and cash equivalents of $286.5 million at quarter end, with total liabilities of $142.2 million.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

PROCEPT BioRobotics Corporation Hedge Fund Activity

We have seen 162 institutional investors add shares of PROCEPT BioRobotics Corporation stock to their portfolio, and 149 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC removed 3,382,944 shares (-42.1%) from their portfolio in Q4 2025, for an estimated $106,427,418
BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. added 2,002,389 shares (+183.3%) to their portfolio in Q4 2025, for an estimated $62,995,157
WESTFIELD CAPITAL MANAGEMENT CO LP removed 1,970,147 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $61,980,824
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,667,045 shares (-81.2%) from their portfolio in Q4 2025, for an estimated $52,445,235
PROSIGHT MANAGEMENT, LP added 1,303,009 shares (+1692.4%) to their portfolio in Q4 2025, for an estimated $40,992,663
LOOMIS SAYLES & CO L P removed 983,903 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $30,953,588
AXA S.A. removed 850,490 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $30,353,988

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

PROCEPT BioRobotics Corporation Analyst Ratings

Wall Street analysts have issued reports on $PRCT in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Truist Securities issued a "Buy" rating on 12/18/2025
UBS issued a "Buy" rating on 12/12/2025
TD Cowen issued a "Buy" rating on 11/05/2025
Oppenheimer issued a "Outperform" rating on 09/02/2025

To track analyst ratings and price targets for PROCEPT BioRobotics Corporation, check out Quiver Quantitative's $PRCT forecast page.

PROCEPT BioRobotics Corporation Price Targets

Multiple analysts have issued price targets for $PRCT recently. We have seen 9 analysts offer price targets for $PRCT in the last 6 months, with a median target of $34.0.

Here are some recent targets:

Craig Bijou from B of A Securities set a target price of $20.0 on 02/26/2026
Joshua Jennings from TD Cowen set a target price of $34.0 on 02/26/2026
Matt O'Brien from Piper Sandler set a target price of $28.0 on 02/26/2026
Nathan Treybeck from Wells Fargo set a target price of $34.0 on 02/26/2026
Mike Kratky from Leerink Partners set a target price of $30.0 on 02/26/2026
Richard Newitter from Truist Securities set a target price of $47.0 on 12/18/2025
Danielle Antalffy from UBS set a target price of $62.0 on 12/12/2025